Source study found
Story checked
Unexpected link identified between rare metabolic disease gene and inherited blindness (opens in a new tab)
medicalxpress.com · 2026-10-06
Short answer
Needs reviewStudy found.
We found the study, but the claim check did not finish.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Unexpected link identified between rare metabolic disease gene and inherited blindness
medicalxpress.com · 2026-10-06
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
We found the study behind this story.
We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.
Open claim evidenceThe source study
Hypomorphic IDUA genotypes are associated with retinitis pigmentosa in individuals without syndromic mucopolysaccharidosis type I
Evidence layer
Claim by claim
The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedResearchers at the Greenwood Genetic Center led the discovery of an unexpected connection between inherited blindness and a gene known for causing a rare metabolic disorder.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 2 of 5Not checkedThe international study examined 14 individuals from 12 families with retinitis pigmentosa, and genetic testing found that all carried changes in both copies of the IDUA gene, which is typically associated with mucopolysaccharidosis type I.View evidenceHide evidence
As stated14 individuals from 12 families
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 3 of 5Not checkedMany of the affected individuals did not have the broader health problems typically associated with mucopolysaccharidosis type I, even at older ages.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 4 of 5Not checkedFunctional studies suggested that some of the IDUA variants allow a very small amount of enzyme activity to remain, which may help explain why these individuals developed retinal disease without widespread MPS I features.View evidenceHide evidence
As stateda very small amount of enzyme activity
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 5 of 5Not checkedThe findings broaden the known range of conditions associated with IDUA and suggest IDUA should be considered when evaluating patients with inherited retinal disease, even when they do not have typical MPS I features.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Hypomorphic IDUA genotypes are associated with retinitis pigmentosa in individuals without syndromic mucopolysaccharidosis type I
The American Journal of Human Genetics · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
Crossref, PubMed, Europe PMC · 16 candidate papers
Hypomorphic IDUA genotypes are associated with retinitis pigmentosa in individuals without syndromic mucopolysaccharidosis type I
The American Journal of Human Genetics · 2026 · Crossref
Homozygous R383H variant in IDUA gene causing pericentric retinitis pigmentosa in attenuated mucopolysaccharidosis type I.
Ophthalmic Genetics · 2026 · PubMed, Europe PMC, Crossref
Retinitis Pigmentosa Due to Rp1 Biallelic Variants
Scientific Reports · 2020 · Crossref
Genetic Insights and Diagnostic Challenges in Highly Attenuated Lysosomal Storage Disorders.
2025 · Europe PMC
Retinitis Pigmentosa
SpringerReference · Crossref
Non-viral delivery of genome-editing tools for treatment of genetic disorders.
2026 · Europe PMC
And 10 more candidates considered.